BEAMSTART Logo

Calidi Biotherapeutics Announces Pricing of $7.5 Million Public Offering of Common Stock

Benzinga LogoBenzinga13h ago

Calidi Biotherapeutics Announces Pricing of $7.5 Million Public Offering of Common Stock - Benzinga

Quick Summary:

SAN DIEGO, Nov.14, 2024 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc.(NYSE:CLDI) ("Calidi" or the "Company"), a clinical-stage biotechnology company developing a new generation of targeted immunotherapies, today announced that it has priced its public offering of 4,437,869 shares of the Company's common stock at a price of $1.69 per share.

The registered direct offering is being made only by means of a prospectus, including a prospectus supplement, which is part of the effective registration statement, that will be filed with the SEC. Electronic copies of the final prospectus supplement and accompanying prospectus may be obtained, when available, on the SEC's website at by contacting Ladenburg Thalmann & Co.Inc., Prospectus Department, 640 ...

The securities described above (excluding the warrants and the shares of common stock underlying the warrants) are being offered pursuant to a shelf registration statement on Form S-3 (File No.333-282456), which was declared effective by the United States Securities and Exchange Commission ("SEC") on October 10, 2024.


More Pictures

Calidi Biotherapeutics Announces Pricing of $7.5 Million Public Offering of Common Stock - Benzinga (Picture 1)

or

Article Details

Author / Journalist: Globe Newswire

Category: InvestingBusiness

Markets:

Topics:

Source Website Secure: Yes (HTTPS)

News Sentiment: Negative

Fact Checked: Legitimate

Article Type: News Report

Published On: 2024-11-14 @ 13:30:00 (13 hours ago)

News Timezone: GMT +8:00

News Source URL: benzinga.com

Language: English

Article Length: 858 words

Reading Time: 5 minutes read

Sentences: 26 lines

Sentence Length: 33 words per sentence (average)

Platforms: Desktop Web, Mobile Web, iOS App, Android App

Copyright Owner: © Benzinga

News ID: 23585905

View Article Analysis

About Benzinga

Benzinga Logo

Main Topics: InvestingBusiness

Official Website: benzinga.com

Update Frequency: 1 posts per day

Year Established: 2010

Headquarters: United States

News Last Updated: 1 days ago

Coverage Areas: United States

Ownership: Independent Company

Publication Timezone: GMT +8:00

Content Availability: Worldwide

News Language: English

RSS Feed: Available (XML)

API Access: Available (JSON, REST)

Website Security: Secure (HTTPS)

Publisher ID: #54

Publisher Details

Frequently Asked Questions

How long will it take to read this news story?

The story "Calidi Biotherapeutics Announces Pricing of $7.5 Million Public Offering of Common Stock" has 858 words across 26 sentences, which will take approximately 4 - 8 minutes for the average person to read.

Which news outlet covered this story?

The story "Calidi Biotherapeutics Announces Pricing of $7.5 Million Public Offering of Common Stock" was covered 13 hours ago by Benzinga, a news publisher based in United States.

How trustworthy is 'Benzinga' news outlet?

Benzinga is a fully independent (privately-owned) news outlet established in 2010 that covers mostly investing and business news.

The outlet is headquartered in United States and publishes an average of 1 news stories per day.

It's most recent story was published 1 days ago.

What do people currently think of this news story?

The sentiment for this story is currently Negative, indicating that people regard this as "bad news".

How do I report this news for inaccuracy?

You can report an inaccurate news publication to us via our contact page. Please also include the news #ID number and the URL to this story.
  • News ID: #23585905
  • URL: https://beamstart.com/news/calidi-biotherapeutics-announces-pricing-of-173159

BEAMSTART

BEAMSTART is a global entrepreneurship community, serving as a catalyst for innovation and collaboration. With a mission to empower entrepreneurs, we offer exclusive deals with savings totaling over $1,000,000, curated news, events, and a vast investor database. Through our portal, we aim to foster a supportive ecosystem where like-minded individuals can connect and create opportunities for growth and success.

© Copyright 2024 BEAMSTART. All Rights Reserved.